Tillman Hartley LLC’s Vertex Pharmaceuticals VRTX Stock Holding History

Tillman Hartley LLC’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$227K	Sell	508 -32	-6%	-$14.9K	0.06%	81
2025 Q4	$245K	Buy	540 +4	+0.7%	+$1.72K	0.06%	84
2025 Q3	$210K	Hold	536	–	–	0.05%	86
2025 Q2	$239K	Hold	536	–	–	0.07%	85
2025 Q1	$260K	Hold	536	–	–	0.08%	71
2024 Q4	$216K	Hold	536	–	–	0.06%	80
2024 Q3	$249K	Hold	536	–	–	0.07%	71
2024 Q2	$251K	Hold	536	–	–	0.09%	70
2024 Q1	$224K	Hold	536	–	–	0.08%	76
2023 Q4	$218K	Buy	+536	New	+$198K	0.08%	73

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Tillman Hartley LLC's VRTX Position: Q1 2026 in Review

Tillman Hartley LLC reduced its Vertex Pharmaceuticals (VRTX) stake by 5.9% in Q1 2026, selling an estimated $14.9K and leaving 508 shares worth $227K. The position accounts for 0.06% of the portfolio, ranked #81.

Tillman Hartley LLC first reported a position in VRTX in Q4 2023 and has held it in 10 quarters since. The position peaked at $260K in Q1 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Tillman Hartley LLC held 508 shares of Vertex Pharmaceuticals worth $227K as of Q1 2026.
Tillman Hartley LLC sold 32 Vertex Pharmaceuticals shares in Q1 2026, an estimated $14.9K.
Vertex Pharmaceuticals made up 0.06% of Tillman Hartley LLC's portfolio in Q1 2026, its #81 holding.
Tillman Hartley LLC first reported a position in Vertex Pharmaceuticals in Q4 2023 and has held it in 10 quarters since.
Tillman Hartley LLC's Vertex Pharmaceuticals position peaked at $260K in Q1 2025.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Tillman Hartley LLC's 13F filing for Q1 2026, filed 8 May 2026.